Walgreens is set to go private after shareholder approval of its takeover. (Photo by Spencer ... More Platt/Getty Images)Getty ImagesWalgreens Boots Alliance Inc. has taken a major step forward in its bid to go private after it announced that at the Company’s Special Meeting of Shareholders, WBA shareholders had approved the previously announced acquisition of the company by entities affiliated with Sycamore Partners Management.According to the preliminary results, approximately 96% of votes cast at the Spe ...

Walgreens Shareholders Approve $10 Billion Private Equity Buyout https://t.co/rfr8G1ht6b https://t.co/rfr8G1ht6b ...

Walgreens Shareholders Approve $10 Billion Private Equity Buyout https://t.co/KT02Viw5Kv https://t.co/KT02Viw5Kv ...

Core Points - Walgreens Boots Alliance shareholders approved Sycamore Partners' $10 billion buyout offer, with the deal expected to close in the third or fourth quarter of 2025, pending regulatory approvals [2][5] - The buyout offer is priced at $11.45 per share, representing a 29% premium over Walgreens' stock price in December [3] - Approximately 96% of votes cast during the special shareholder meeting were in favor of the merger [4] Company Strategy - The CEO of Walgreens expressed appreciation for shareholder support, indicating that the partnership with Sycamore will help accelerate the company's turnaround strategy and improve customer and employee experiences [5] - Walgreens has faced challenges in recent years, including a failed in-store clinic rollout that resulted in store closures and significant financial losses [6] Financial Performance - Walgreens invested over $6 billion in VillageMD to gain a controlling stake, but has since scaled back on clinic expansions due to difficulties in filling patient panels, contributing to a net loss of over $8 billion for fiscal 2024 [7]

Walgreens Boots Alliance (WBA) is one of the largest pharmacy retailers in the United States. Over the past several years, the company has made a number of poor investment decisions. As management looks to turn the business around, Walgreens has become a special situation stock.There are very important implications to consider before you buy the shares today. Here are three things you need to know if you are considering buying Walgreens stock today.1. Walgreens is a special situations stockThe term "special ...

Core Insights - Walgreens Boots Alliance reported a quarterly loss that was better than expected, with rising pharmacy sales indicating potential for financial recovery under new private equity ownership [2] - The acquisition by Sycamore Partners, valued at $10 billion, is anticipated to lead to significant cost-cutting measures [3] - Shareholder approval for the acquisition is scheduled for a special meeting on July 11, with no serious opposition reported [4] Financial Performance - In the fiscal third quarter, Walgreens reported a net loss of $175 million, or 20 cents per share, compared to a net income of $344 million, or 40 cents per share, in the same period last year [5] - Total sales increased by 7% to $39 billion in the third quarter [5] - The U.S. Healthcare segment generated $2.1 billion in sales, with an operating loss of $64 million, significantly improved from a $220 million loss in the previous year [6] Cash Flow and Cost Management - Analysts noted Walgreens' ability to generate positive free cash flow in the quarter, a significant improvement given recent negative trends [7] - The company is on track to meet its goal of closing 1,200 underperforming stores by fiscal 2027, having already closed over 400 stores in the first nine months of the fiscal year [8] Strategic Outlook - The transition to private ownership is viewed positively, allowing Walgreens to focus on long-term reinvention without the pressures of public market expectations [10] - The company aims to close 500 stores in the current fiscal year as part of its cost-saving initiatives [8]

Core Insights - Walgreens is experiencing an increase in sales as it prepares for a transition to private ownership, with a deal expected to close in the second half of 2025 for $10 billion [3]. Financial Performance - The company reported quarterly earnings showing sales of $39 billion, reflecting a 7.2% increase year-over-year, driven by growth in its U.S. retail pharmacy and international segments [2]. - The U.S. retail pharmacy segment achieved quarterly sales of $30.7 billion, up 7.8% year-over-year, with comparable sales increasing by 10.3%. Pharmacy sales specifically rose by 11.8% for the quarter [4]. - However, retail sales fell by 5.3%, attributed to weaker performance in grocery, household, health and wellness, and beauty categories [4]. Economic Context - The broader economic environment shows a contraction, with the economy shrinking by 0.5% in the first quarter, a downward revision from a previously estimated 0.2% dip [5]. - Consumer spending is declining, influenced by new tariffs, leading to changes in shopping behaviors among consumers [6][5]. Strategic Focus - The company is committed to a turnaround plan that emphasizes a disciplined approach to managing cash needs while investing in necessary adaptations to the evolving pharmacy and retail landscape [3].

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Thursday.The Dow traded up 0.82% to 43,335.29 while the NASDAQ gained 0.69% to 20,110.81. The S&P 500 also rose, gaining, 0.66% to 6,132.29.Check This Out: AMD, Taiwan Semiconductor And A Financial Stock On CNBC’s ‘Final Trades’Leading and Lagging SectorsMaterials shares jumped by 0.9% on Thursday.In trading on Thursday, real estate stocks fell by 1%.Top HeadlineWalgreens Boots Alliance Inc WBA on Thursday ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Walgreens Boots Alliance (WBA) reported $38.99 billion in revenue for the quarter ended May 2025, representing a year-over-year increase of 7.3%. EPS of $0.38 for the same period compares to $0.63 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $36.61 billion, representing a surprise of +6.49%. The company delivered an EPS surprise of +11.76%, with the consensus EPS estimate being $0.34.While investors scrutinize revenue and earnings changes year-over-year and how they compare wi ...